Rothschild & Co. Asset Management US Inc. Has $5.61 Million Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Rothschild & Co. Asset Management US Inc. lessened its holdings in shares of AtriCure, Inc. (NASDAQ:ATRCGet Rating) by 27.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 85,403 shares of the medical device company’s stock after selling 31,634 shares during the period. Rothschild & Co. Asset Management US Inc. owned approximately 0.18% of AtriCure worth $5,608,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Truist Financial Corp lifted its position in shares of AtriCure by 0.9% during the 1st quarter. Truist Financial Corp now owns 21,062 shares of the medical device company’s stock worth $1,383,000 after purchasing an additional 185 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in AtriCure by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,341 shares of the medical device company’s stock valued at $162,000 after acquiring an additional 215 shares in the last quarter. Mount Yale Investment Advisors LLC raised its holdings in AtriCure by 5.6% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 4,550 shares of the medical device company’s stock valued at $299,000 after acquiring an additional 243 shares in the last quarter. Advisor Group Holdings Inc. raised its holdings in AtriCure by 3.1% in the 1st quarter. Advisor Group Holdings Inc. now owns 12,039 shares of the medical device company’s stock valued at $790,000 after acquiring an additional 357 shares in the last quarter. Finally, Huntington National Bank raised its holdings in AtriCure by 767.3% in the 1st quarter. Huntington National Bank now owns 451 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 399 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a report on Wednesday. BTIG Research cut their price target on AtriCure from $94.00 to $75.00 and set a “buy” rating for the company in a report on Friday, June 24th. Piper Sandler cut their price target on AtriCure from $90.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, August 3rd. Needham & Company LLC increased their target price on AtriCure from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Finally, Stifel Nicolaus dropped their target price on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $75.86.

AtriCure Stock Up 2.7 %

NASDAQ ATRC opened at $45.25 on Friday. The firm has a market cap of $2.10 billion, a PE ratio of 39.01 and a beta of 1.21. AtriCure, Inc. has a one year low of $32.83 and a one year high of $89.18. The stock’s 50 day simple moving average is $46.56 and its 200 day simple moving average is $50.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93.

AtriCure (NASDAQ:ATRCGet Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same period in the prior year, the business earned ($0.30) earnings per share. As a group, sell-side analysts forecast that AtriCure, Inc. will post -1.09 earnings per share for the current fiscal year.

AtriCure Profile

(Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Featured Stories

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRCGet Rating).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.